NF2 and meningioma: The only trial to enroll meningioma patients alone is A071401, a Phase 2 trial of SMO/AKT/NF2/CDK inhibitors in patients with progressive meningiomas harboring corresponding mutations in the respective signaling pathway (NCT02523014).